China

AI Citation Summary

• Country: China
• Product line: Medical devices
• Regulator / source: Regulatory Maturity: Highly mature. The regulatory framework has undergone intensive reform (major revisions in 2017, 2020, and 2021). Technical review capacity has improved rapidly, with a clear trend toward international alignment — though local implementation specifics remain distinctive.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Classification and pathway - Class I filing, Class II registration, Class III registration, or IVD? - Imported Class I devices are filed with NMPA; imported Class II/III devices are generally reviewed by NMPA / CMDE, with materially different timelines
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 1.41 billion (2024)
• Healthcare System: Predominantly public hospitals (three-tier system with tertiary/Grade III-A hospitals at the top), supplemented by private hospitals and internet-based healthcare; universal basic health insurance coverage exceeds 95%
• Market Characteristics: World's second-largest medical device market, with an estimated market size of approximately CNY 1.2 trillion in 2023. Domestic substitution and localisation policies are aggressively pursued; volume-based procurement (VBP) for high-value consumables has become routine. Grade III-A hospitals are the primary channel for premium devices; the grassroots/primary care market holds substantial growth potential.
• Regulatory Maturity: Highly mature. The regulatory framework has undergone intensive reform (major revisions in 2017, 2020, and 2021). Technical review capacity has improved rapidly, with a clear trend toward international alignment — though local implementation specifics remain distinctive.

Market-Entry Logic

China medical-device entry should be separated into NMPA classification / filing / registration, CMDE technical review, domestic responsible agent, Chinese technical dossier and labelling, clinical evaluation or local clinical trial, registration testing / product technical requirements, import and distribution qualification, UDI / post-market surveillance, procurement listing, VBP pricing, and import-substitution pressure. For foreign manufacturers, the registration certificate is only the compliance starting point; commercial success depends on public hospital procurement platforms, Grade III hospital departments, service networks, and provincial / national procurement rules.

Entry layer	Key question	Practical view
Classification and pathway	Class I filing, Class II registration, Class III registration, or IVD?	Imported Class I devices are filed with NMPA; imported Class II/III devices are generally reviewed by NMPA / CMDE, with materially different timelines
Domestic responsible agent	Who serves as China agent, regulatory interface, and post-market executor?	Foreign applicants must designate a China-registered enterprise legal person; agent capability affects deficiency responses, variations, recalls, and service response
Technical and clinical evidence	Can CE / FDA files, clinical evaluation, overseas clinical data, China clinical data, and test reports be converted?	Overseas evidence helps, but Chinese classification, product technical requirements, Chinese dossier, clinical exemption, and testing requirements need item-by-item confirmation
Commercial access	After registration, can the product be listed on procurement platforms and adopted by hospitals?	High-value consumables and equipment need provincial listing, hospital access, service engineers, training, and receivables management alongside registration
Pricing and import substitution	Is the target category already in, or exposed to, VBP / high-value consumable procurement?	Imported brands in joints, spine, coronary, IOL, and similar categories must assess price erosion and domestic-substitution pressure before filing

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	NMPA, CMDE, provincial drug administrations, NIFDC, adverse-event monitoring system	Determine classification, registration / filing, technical review, testing, UDI, PMS, and variations
Payment / procurement	NHSA, national and provincial procurement platforms, sunshine procurement platforms, public hospital purchasing offices	Determine consumable codes, listing, pricing, tender access, and public-hospital purchasing restrictions
Domestic medtech leaders	Mindray, United Imaging, MicroPort, Lepu Medical, Weigao, Wondfo, Sinocare, and other IVD / consumable players	Create strong local competition in monitoring, imaging, cardiovascular, orthopaedics, consumables, IVD, and primary-care channels
Multinational device companies	GE HealthCare, Siemens Healthineers, Philips, Medtronic, Johnson & Johnson MedTech, Abbott, BD and similar players	Still strong in high-end imaging, intervention, consumables, diagnostics, and training systems, but constrained by VBP and import substitution
Channel and service	Provincial distributors, hospital equipment-department channels, repair service providers, third-party logistics	Execute listing, tenders, installation, clinical training, maintenance, spare parts, receivables, and regional coverage
End-use settings	Grade III hospitals, regional medical centers, county hospitals, private specialty hospitals, check-up and laboratory chains	Drive high-end reference use, lower-tier volume, consumable pull-through, and home / POCT access

Development Trends

1. High-end innovative devices receive policy support, but lifecycle supervision is more detailed: NMPA continues to support high-end devices, AI, robotics, biomaterials, and innovative-product special review while strengthening standards, clinical evaluation, and post-market evidence.
2. Import substitution is moving into higher-end categories: Imaging, monitoring, IVD, orthopaedics, cardiovascular, and surgical robotics all face faster domestic competition.
3. VBP and procurement listing define the business model: High-value consumables may be repriced after registration; capital equipment is shaped by budgets, configuration controls, service, and localisation expectations.
4. Domestic responsible agent and service network are critical moats for imported brands: Registration agency alone is not enough; hospitals require installation, training, repair, spare parts, and adverse-event response.
5. UDI, data linkage, and real-world evidence are becoming more important: Registration, procurement, traceability, post-market surveillance, and hospital-use data are increasingly connected.

Regulatory Authority

• Competent Authority: National Medical Products Administration (NMPA), formerly CFDA/SFDA
• Official Portals: https://www.nmpa.gov.cn; Medical Device Registration System: https://ectd.nmpa.gov.cn
• Key Regulations:
  • Regulations for the Supervision and Administration of Medical Devices (2021 revision, State Council Decree No. 739)
  • Administrative Measures for Medical Device Registration and Filing (2021, NMPA Order No. 47)
  • Administrative Measures for Registration and Filing of In Vitro Diagnostic Reagents (2021, NMPA Order No. 48)
  • Good Clinical Practice for Medical Device Clinical Trials (2022)
  • Requirements and Instructions for Medical Device Registration Dossiers (category-specific guidance documents)

Device Classification System

Local Classification	Risk Level	EU/FDA Equivalent	Description
Class I	Low risk	EU Class I / FDA Class I	Filing (备案) system; handled by provincial drug regulatory authorities; clinical data generally not required
Class II	Moderate risk	EU Class IIa/IIb / FDA Class II	Registration system; approved by provincial authorities (some categories by NMPA); most require clinical evidence
Class III	High risk	EU Class III / FDA Class III/PMA	Registration system; technical review conducted directly by NMPA/CMDE; virtually all require clinical trial data or a clinical exemption

Note: IVDs have a separate classification system (Class I through Class III), and classification criteria may differ from non-IVD devices. Refer to the Medical Device Classification Catalogue (2017 edition, with subsequent updates).

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.